Evidence map›Paper›PMID 39343865›Full record

Trial reportAIDS and behavior2024

Adolescent Girls and Young Women Overcoming Adherence Challenges with Vaginal and Oral PrEP Use: A Longitudinal Qualitative Study from a Crossover Trial in South Africa, Uganda, and Zimbabwe.

Mary Kate Shapley-Quinn, Siyanda Tenza, Destry Jensen, Thelma Tauya, Lydia Mampuru, Juliane Etima, Doreen Kemigisha, Millicent Atujuna, Lydia Soto-Torres, Sherri Johnson and 4 more

Registry-linked trialAbstract readClinical Trial, Phase II
In one paragraph

Trial report in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03593655 (A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03593655 phase2completednot on this map

A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2021Enrolled247ConditionsHIV InfectionsArmsDapivirine vaginal ring, FTC/TDF
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mary Kate Shapley-QuinnWomen's Global Health Imperative, RTI International, Berkeley, CA, USA. mshapley@rti.org.ORCID http://orcid.org/0000-0001-9805-3132
Siyanda TenzaWits Reproductive Health and HIV Institute, Johannesburg, South Africa.
Destry JensenDivision of Global Emergency Medicine, Brown University, Kigali, Rwanda.
Thelma TauyaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Lydia MampuruWits Reproductive Health and HIV Institute, Johannesburg, South Africa.
Juliane EtimaMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.ORCID http://orcid.org/0000-0002-5879-6000
Doreen KemigishaMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Millicent AtujunaDesmond Tutu HIV Centre, Cape Town, South Africa.ORCID http://orcid.org/0000-0003-1287-2634
Lydia Soto-TorresDivision of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Sherri Johnson, FHI 360, Durham, NC, USA.
Nombeko MpongoDesmond Tutu HIV Centre, Cape Town, South Africa.
Nomsa MhlangaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Kenneth NgureSchool of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.ORCID http://orcid.org/0000-0002-8062-0933
Ariane van der StratenCenter for AIDS Prevention Studies, Department of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8536-648X

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
National Institute of Allergy and Infectious Diseases UM1AI068615National Institute of Allergy and Infectious Diseases UM1AI068633National Institute of Allergy and Infectious Diseases UM1AI106707NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

Rates of HIV acquisition remain high among adolescent girls and young women (AGYW) in sub-Saharan Africa. We explored South African, Ugandan, and Zimbabwean AGYW's experiences in a crossover trial of two HIV prevention products: Daily oral pre-exposure prophylaxis pills and a monthly dapivirine vaginal ring. A subset of participants (n = 25) across all sites completed up to three serial in-depth interviews (SIDIs). The SIDIs explored barriers to product use, coping strategies, and the resulting outcomes. Coded textual data were analyzed using a product acceptability conceptual framework. Participants in the SIDIs described managing the array of challenges they encountered through formal adherence support, strategic product disclosure, and personally adapted strategies. For both products, perceived discreetness of the product and decision-making around disclosure was an important component of participants' narratives. Participants tailored their coping strategies based on available personal resources (e.g., cell phone alarms for PrEP reminders, social support through disclosure) or study provided resources (e.g., encouragement from staff, adherence groups). Notably, challenges participants encountered with each product during the crossover period helped inform product selection during the choice period. Our findings suggest that-even in a context where AGYW have access to several options for HIV prevention-challenges to consistent product use remain, but accessible support mechanisms and informed choice can help mitigate these challenges. Enacting that choice may also empower AGYW to reach their short and long-term life goals-including for HIV prevention. (NCT03593655, 20th July 2018).

Indexed as

Anti-HIV AgentsContraceptive Devices, FemaleDrug MonitoringHIV InfectionsMedication AdherencePre-Exposure ProphylaxisAdaptation, PsychologicalAdministration, IntravaginalAdministration, OralAdolescentAdultCross-Over StudiesFemaleHumansInterviews as TopicLongitudinal StudiesAnti-HIV AgentsDapivirinePyrimidinesAdherence supportAdolescent girls and young womenHIV preventionPre-exposure prophylaxisQualitativeSub-Saharan Africa

Identifiers

PMID39343865
PMCPMC11586305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.